IPH4502
IPH4502, our Antibody Drug Conjugate targeting Nectin-4
Innate Pharma Reports First Half 2025 Business Update And Financial Results
IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3...
Innate Pharma announces its participation in the 25th edition of the European Midcap Event
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition...
John Powderly et al, 2025.
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors
American Association for Cancer Research journals
Innate Pharma announces conference call and webcast for first half 2025 financial results and business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8...
Number of shares and voting rights of Innate Pharma as of September 1, 2025
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...
Number of shares and voting rights of Innate Pharma as of August 1, 2025
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...
Innate Pharma announces its participation in BTIG virtual biotechnology conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual...
Number of shares and voting rights of Innate Pharma as of July 3, 2025
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...
Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed...